Department of Public Health, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan.
PLoS One. 2022 Apr 11;17(4):e0266771. doi: 10.1371/journal.pone.0266771. eCollection 2022.
Gonadotropin-releasing hormone (GnRH) analogues reduce testosterone levels to castration levels in patients with prostate cancer. However, the role of testosterone in atopic diseases has remained undefined. We aimed to investigate this role.
This retrospective cohort study was conducted using the National Health Insurance Research Database (NHIRD). Patients with prostate cancer were categorized into two groups according to whether they received GnRH analogue treatment (study group I) or not (study group II), and men without prostate cancer and with no GnRH analogue use were defined to comprise the comparison group after their ages and index years were matched with group II. Cox proportional hazard models were used to assess the hazard ratio (HR) of atopic diseases.
Group I, group II, and the comparison group comprised 663, 2,172, and 8,688 individuals, respectively. Group I had a significantly lower risk of atopic diseases (adjusted HR: 0.66, 95% CI, 0.49-0.89, p < 0.01) than did group II. A reduced risk of atopic diseases was found when GnRH analogues were prescribed for 2 months (adjusted HR 0.53, 95% CI, 0.29-0.97, p = 0.04) and 2-14 months (adjusted HR 0.66, 95% CI, 0.49-0.89, p = 0.007). No significant difference in the risk of atopic diseases between group II and the comparison group was observed.
A decreased risk of atopic diseases was observed in patients with prostate cancer treated with GnRH analogues. Further studies are warranted to verify the association between testosterone levels and atopic diseases.
促性腺激素释放激素（GnRH）类似物可降低前列腺癌患者的睾酮水平至去势水平。然而，睾酮在特应性疾病中的作用仍未确定。我们旨在研究这一作用。
本回顾性队列研究使用了全民健康保险研究数据库（NHIRD）。根据是否接受 GnRH 类似物治疗（研究组 I）将前列腺癌患者分为两组，未接受 GnRH 类似物治疗且无前列腺癌的男性在年龄和指数年份与组 II 匹配后被定义为对照组。使用 Cox 比例风险模型评估特应性疾病的风险比（HR）。
组 I、组 II 和对照组分别包含 663、2172 和 8688 名个体。组 I 的特应性疾病风险显著降低（调整后的 HR：0.66，95%CI，0.49-0.89，p<0.01），明显低于组 II。当 GnRH 类似物处方 2 个月（调整后的 HR 0.53，95%CI，0.29-0.97，p=0.04）和 2-14 个月（调整后的 HR 0.66，95%CI，0.49-0.89，p=0.007）时，特应性疾病的风险降低。组 II 和对照组之间特应性疾病的风险无显著差异。
接受 GnRH 类似物治疗的前列腺癌患者特应性疾病的风险降低。需要进一步的研究来验证睾酮水平与特应性疾病之间的关联。
